Our Investment Model
A differentiated cross-border platform that combines venture building in Spain with growth investing in the United States to create long-term value for investors and biotechnology companies.
Built around the complementary strengths of the Spanish and U.S. biotechnology ecosystems, our model combines scientific excellence, strategic acceleration, and disciplined investing within a single investment platform.
Investing in Spain
From Scientific Innovation to Global Biotechnology Companies
Spain has become one of Europe's fastest-growing biotechnology ecosystems, producing outstanding science, internationally recognized clinical research, and an increasing number of innovative entrepreneurs. The Fund identifies high-potential companies capable of becoming globally competitive biotechnology leaders.
The Translational Unit
A specialized team operating simultaneously in Spain and Boston forms the foundation of the Fund's investment strategy in Spain.
In Spain, the team evaluates scientific innovation emerging from biotechnology companies, research centers, hospitals, and universities. At the same time, the Boston team maintains an active dialogue with global pharmaceutical companies to understand their strategic pipeline priorities and future licensing needs.
Only opportunities that combine exceptional science with demonstrated commercial interest from pharmaceutical partners advance to the Fund's investment process.
Accelerating Through Boston
Following investment, portfolio companies are supported in establishing a strategic presence in Boston by creating a U.S. subsidiary. This provides direct access to investors, pharmaceutical companies, strategic partners, experienced executives, and one of the world's leading biotechnology ecosystems, helping accelerate growth and maximize long-term value creation.
Investing in the United States
Investing in Proven Innovation
Complementing its activities in Spain, the Fund invests directly in compelling U.S.-based biotechnology companies, with a strategic emphasis on Boston and Massachusetts.
The investment strategy focuses primarily on later-stage biotechnology companies with strong scientific validation, experienced management teams, differentiated technologies, and attractive risk-adjusted return profiles.
These investments provide exposure to one of the world's leading biotechnology markets while creating a balanced portfolio and additional opportunities for long-term value creation.
INVESTORS
Access a differentiated cross-border investment platform that combines two complementary strategies to generate long-term value.
BIOTECH COMPANIES
Partner with an experienced team that provides capital, strategic guidance, and access to world-class ecosystems to accelerate your growth.
STRATEGIC PARTNERS
Collaborate with a cross-border platform that connects innovation, capital, and expertise to create sustainable impact.